Genmab A/S (GMAB) Stock Analysis
Healthcare · Biotechnology
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma... Read more
TrendMatrix rates Genmab A/S (GMAB) as Hold with moderate confidence. The stock trades at $26.11 with +22.6% upside to the $32.00 price target. Overall score: 5.8/10 across 10 analysis dimensions. Reward/risk ratio: 3.1:1.
Passes 4/4 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags). Suitability: moderate.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates Genmab A/S (GMAB) as Hold with moderate confidence. Score 5.8/10.
Take-profit target: $32.00 (+22.6% upside). Reward/risk ratio: 3.1:1. Stop-loss: $24.20.
Weak growth; Below 200-day MA.
Genmab A/S trades at a P/E of 16.7 (forward 14.4). TrendMatrix value score: 7.4/10. Verdict: Hold.
26 analysts cover GMAB with a consensus score of 3.7/5. Average price target: $38.
What does Genmab A/S do?Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of...
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.